President and Chief Executive Officer · Dyne Therapeutics, Inc. (DYN)

Joshua Brumm

A named executive officer of Dyne Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,317,103

Salary $610,000Stock awards $1,709,371

FY2021: $4,086,611

1st of 3 named executive officers at Dyne Therapeutics by FY2022 total.

3 named officers on file for Dyne Therapeutics, FY2022

Joshua Brumm’s pay file — $29

  • 4 fiscal years of pay, line by line
  • DYN’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Dyne Therapeutics’s whole pay program stands against its peers

  • Dyne Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DYN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 7, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joshua Brumm’s full pay file as a PDF — free

More than this page: up to 10 years of Joshua’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joshua Brumm compensation by year

Dyne Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Dyne Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022
Salary$97,212$482,667$562,000$610,000
Bonus$180,000$0$0$0
Stock awards$0$3,134,366$1,550,653$1,709,371
Option awards$0$7,944,295$1,509,121$1,661,236
Non-equity incentive$0$299,877$451,830$335,500
Pension and deferred compensation$0$0$0$0
All other$102$6,900$13,007$996
Total$277,314$11,868,105$4,086,611$4,317,103

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dyne Therapeutics, Inc. DEF 14A filed April 7, 2023, accession 0000950170-23-012196, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Dyne Therapeutics, Inc. filed document, accession 0000950170-23-012196. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2023.

$277K
$11.9M
$4.1M
$4.3M
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU144,000$1,668,960—
RSU88,644$1,027,384—
RSU53,513$620,216—
Option222,000—$10.72
Option134,691—$5.54
Option139,438—$1.03
Option165,952—$5.54
Option140,342—$19.00
Option132,964—$13.12

Per the Outstanding Equity Awards at Fiscal Year-End table in Dyne Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

53 Form 4 lines since the FY2022 proxy (filed April 7, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-03-11Sale10b5-18,618$25.93537,998
2024-03-11Sale10b5-140,072$25.42564,313
2024-03-11Sale10b5-19,928$26.10554,385
2024-03-11Sale10b5-17,769$26.12546,616
2024-03-11Exercise or conversion10b5-150,000$5.54604,385
2024-03-11Exercise or conversion derivative10b5-150,000$0.0083,269
2024-03-08Sale10b5-1435$27.38554,385
2024-03-08Sale10b5-1160,670$26.72554,820

The 8 most recent of 53 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Dyne Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Joshua Brumm · this pagePresident and Chief Executive Officer$4,317,103
Susanna HighChief Operating Officer$1,594,292
Oxana BeskrovnayaChief Scientific Officer$1,486,373

Board service

Dyne Therapeutics board · FY2021–FY2022

How this board is paid

Company policy: Dyne Therapeutics pays directors a $35,000 cash retainer. As stated in Dyne Therapeutics's FY2022 proxy.

The full Dyne Therapeutics compensation record

free company brief

This page is one person within Dyne Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Dyne Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dyne Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joshua Brumm's compensation dossier · One-time report. No refunds.